Analytical Data
-
基因名
U69
- Application
-
别名
U69；Leucine-rich repeat-containing Protein 69
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P24446
-
表达区间
170-355aa
-
氨基酸序列
SEERSYSVVYVPHNKELCGQFCQPEKTMARVLGVGAYGKVFDLDKVAIKTANEDESVISAFIAGVIRAKSGADLLSHECVINNLLISNSVCMSHKVSLSRTYDIDLHKFEDWDVRNVMNYYSVFCKLADAVRFLNLKCRINHFDISPMNIFLNHKKEIIFDAVLADYSLSEMHPNYNGTCAIAKEY
-
分子量
25.1 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
U69 is a recombinant protein often studied for its potential applications in various fields, including immunology and vaccine development. Derived from specific viral or bacterial proteins, U69 has gained interest due to its ability to elicit strong immune responses. Research into U69 focuses on understanding its structure-function relationship and how modifications in its recombinant form can enhance its immunogenicity. Studies have shown that U69 can engage various immune cells, leading to the activation of both adaptive and innate immune responses. Furthermore, the production of U69 in expression systems, such as bacteria or yeast, offers a cost-effective means of generating large quantities of the protein for experimental use. As a result, researchers are exploring its potential as a therapeutic agent, particularly in the context of infectious diseases and cancer immunotherapy. The ongoing investigation into U69 not only aims to unravel its biological mechanisms but also seeks to identify its practical applications in designing effective vaccines and treatment strategies.
